No effect of clot age or thrombolysis on argatroban's inhibition of thrombin

Blood

Volumn 92, Issue 6, 1998, Pages 2064-2074

  Hantgan, Roy R ^a   Jerome, W Gray ^b   Hursting, Marcie J ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ARGATROBAN; STREPTOKINASE; THROMBIN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; DOSE RESPONSE; FIBRIN CLOT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THROMBOSIS;

EID: 0032530735     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.6.2064     Document Type: Article

References (41)

1. Jang IK, The MINT Investigators: A randomized study of argatroban vs heparin as adjunctive therapy to tissue plasminogen activator in acute myocardial infarction: MINT (Myocardial Infarction with Novastan and TPA) study. Circulation 96:1-331, 1997 (abstr)
2. Theroux P: A randomized, double-blind, study of two doses of Novastan® (brand of argatroban) versus placebo as adjunctive therapy to streptokinase in acute myocardial infarction. The Argatroban Myocardial Infarction (AMI) Study. J Am Coll Card 29:viii, 1997 (suppl A)
3. Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S: Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methy-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-l- arginyl)]-2-piperidinecarboxylic acid. Biochemistry 23:85, 1984
4. Okamoto S, Hijikata-Okunomiya A: Synthetic selective inhibitors of thrombin. Methods Enzymol 222:328, 1993
5. Banner DW, Hadvary P: Inhibitor binding to thrombin: X-ray crystallographic studies. Adv Exp Med Biol 340:27, 1993
6. Bauer M, Brandstetter H, Turk D, Sturzebecher J, Bode W: Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost 19:352, 1993
7. Berry CN, Girardot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 72:381, 1994
8. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN: Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 75:154, 1996
9. Kleiman NS: Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Coronary Artery Dis 7:508, 1996
10. Schwarz RP Jr, Becker J-CP, Brooks RL, Hursting MJ, Joffrion JL, Knappenberger GD, Kogan TP, Kogan PW, McKinney AA: The preclinical and clinical pharmacology of Novastan (argatroban): A small-molecule, direct thrombin inhibitor. Clin Appl Thromb Hemost 3:1, 1997
11. Verstraete M: Modulating platelet function with selective thrombin inhibitors. Haemost 26:70, 1996 (suppl 4)
12. Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man [see comments]. Circulation 83:1510, 1991
13. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT: Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 84:18, 1989
14. Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S: Effect of a selective thrombin inhibitor MCI9038 on fibrinolysis in vitro and in vivo. Thromb Haemost 56:28, 1986
15. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 67:1552, 1990
16. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 23:197, 1997
17. Lewis BE, Iaffaldano R, McKiernan TL, Rao L, Donkin J, Wallenga JM: Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Calheterization Cardiovasc Diag 38:206, 1996
18. Hantgan RR: A study of the kinetics of ADP-triggered platelet shape change. Blood 64:896, 1984
19. Mattler LE, Bang NU: Serine protease specificity for peptide chromogenic substrates. Thromb Haemost 38:776, 1977
20. Jen CJ, McIntire LV: Platelet microtubules in clot structure formation and contractile force generation: Investigation of a controversy. Thromb Haemost 56:23, 1986
21. Lewis JC, Hantgan RR, Stevenson SC, Thornburg T, Kieffer N, Guichard J, Breton-Gorius J: Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion: Localization to the granulomere and at sites of platelet interaction. Am J Pathol 136:239, 1990
22. Torbet J: The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro. Thromb Haemost 73:785, 1995
23. Hantgan RR, McDonagh J, Hermans J: Fibrin assembly. Ann NY Acad Sci 408:344, 1983
24. Weisel JW: Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 50:1079, 1986
25. Carr ME, Hermans J: Size and density of fibrin fibers from turbidity. Macromolecules 11:46, 1978
26. Mosesson MW: Thrombin interactions with fibrinogen and fibrin. Semin Thromb Hemost 19:361, 1993
27. Hantgan RR: Localization of the domains of fibrin involved in binding to platelets. Biochim Biophys Acta 968:36, 1988
28. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, De Groot PG: Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 76:345, 1990
29. Carr M, Shen LL, Hermans J: Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 16:1, 1977
30. Blomback B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N: Native fibrin gel networks observed by 3D microscopy, permeation, and turbidity. Biochim Biophys Acta 997:96, 1989
31. Nair CH, Azhar A, Dhall DP: Studies on fibrin network structure in human plasma. Part I - Methods for clinical application. Thromb Res 64:455, 1991
32. Tiefenbrunn AJ, Sobel BE: Pharmacodynamics of activation of plasminogen with t-PA, in Sobel BE, Collen D, Grossbard EB (eds): Tissue Plasminogen Activator in Thrombolytic Therapy. New York, NY, Marcel Dekker, 1987, p 25
33. Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz KH, Herrmann KS: Single bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 64:448, 1989
34. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E: Thrombolysis in myocardial infarction (TIMI) trial, phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142, 1987
35. Collen D, Lijnen HR: The fibrinolytic system in man. CRC Crit Rev Oncol Hematatol 4:248, 1985
36. Segel IH: Multiple inhibition analysis, in Davis S (ed): Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York. NY, Wiley, 1975, p 465
37. Wu JH, Siddiquik, Diamond SL: Transpost phenomenon and clot dissolving therapy: An experimental investigation of diffusion controlled and permeation enhanced fibrinolysis. Thromb Haemost 72:105, 1994
38. Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW: Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 71:230, 1993
39. Cantor CR, Schimmel PR: Size and shape of macromolecules, in Biophysical Chemistry. Part II: Techniques for the Study of Biological Structure and Function. San Francisco, CA, Freeman, 1980, p 539
40. Handt S, Jerome WG, Tietze L, Hantgan RR: PAI-1 section by endothelial cellls increases fibrinolytic resistance of an in vitro fibrin clot: Evidence for a key role of endothelial cells in thrombolytic resistance. Blood 87:4204, 1996
41. Blinc A. Francis CW: Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost 76:481, 1996